Saturday, 17 October 2026European Markets

NEW SOURCES ENERGY Stock Bullish By 29% In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of NEW SOURCES ENERGY (AEX-Index: NSE.AS) jumped by a staggering 29.03% in 10 sessions from €0.03 to €0.04 at 05:12 EST on Wednesday, after three successive sessions in a row of losses. AEX-Index is falling 0.97% to €756.67, after two successive sessions in a row of losses.

About NEW SOURCES ENERGY

New Sources Energy N.V. develops, operates, exploits, and invests in projects that generates electricity using renewable energy sources. The company was formerly known as Management Share NV and changed its name to New Sources Energy N.V. in July 2011. New Sources Energy N.V. is headquartered in Amersfoort, the Netherlands.

Volume

Today's last reported volume for NEW SOURCES ENERGY is 22126 which is 69.19% below its average volume of 22012.

Volatility

NEW SOURCES ENERGY's last week, last month's, and last quarter's current intraday variation average was a negative 5.26%, a negative 0.31%, and a positive 7.37%.

NEW SOURCES ENERGY's highest amplitude of average volatility was 5.26% (last week), 9.54% (last month), and 7.37% (last quarter).

More news about NEW SOURCES ENERGY (NSE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com